Neuralstem to Present at Bio-Europe Spring Healthcare Conference, April 8, 2008



ROCKVILLE, Md., April 01, 2008, 2008 /PRNewswire-FirstCall/ -- Stem cell company, Neuralstem, Inc. announced today that Richard Garr, President & Chief Executive Officer, will present at BIO-Europe Spring(R) 2008, in Madrid, Spain, April 7-9. BIO-Europe Spring(R), a counterpart to the BIO-Europe conference in the fall, brings together biotechnology leaders for company presentations and panel discussions. Neuralstem will give an update on the company's clinical trials program when it presents on April 8.




About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.

Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Paraplegia, Traumatic Spinal Cord Injury and ALS. The company's cells have extended the life of rats with ALS (Lou Gehrig's disease), as reported in a paper published in the journal TRANSPLANTATION in collaboration with John's Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego.

The company has also developed immortalized human neural stem cells for in-vitro use in drug development for the academic and pharmaceutical markets. For further information, please visit http://www.neuralstem.com.

Cautionary Statement Regarding Forward Looking Information

This presentation may contain forward-looking information about Neuralstem, Inc. which are intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and Neuralstem's future performance, operations and products. This and other "Risk Factors" contained in Neuralstem's public filings with the SEC should be read in connection with this release. For further information on Neuralstem, please review the company's filings with the SEC including its Annual Report filed on Form 10-KSB for the period ended December 31, 2007, as well as the company's subsequent filings.

CONTACT: Richard Garr, President of Neuralstem Inc., +1-301-366-4960; orMedia: Deanne Eagle of Planet Communications, +1-917-837-5866, forNeuralstem Inc.; or Investor Relations: Ira Weingarten, +1-805-897-1880 orSteve Chizzik, +1-908-688-9111, both of Equity Communications, forNeuralstem Inc.

Web site: http://www.neuralstem.com/
http://www.pharmalive.com/News/index...&categoryid=63